(Q34481243)

2 August 2017

title

Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model (English)

1 reference

2 August 2017

David M Brogan

1

1 reference

2 August 2017

Elias Mossialos

series ordinal

2

1 reference

2 August 2017

publication date

7 November 2013

1 reference

2 August 2017

published in

Globalization and Health

1 reference

2 August 2017

volume

9

1 reference

2 August 2017

page(s)

58

1 reference

https://scigraph.springernature.com/pub.10.1186/1744-8603-9-58

2 August 2017

exact match

0 references

cites work

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Combating antimicrobial resistance: policy recommendations to save lives

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Trends in risks associated with new drug development: success rates for investigational drugs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Estimating the cost of new drug development: is it really 802 million dollars?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Trends in antimicrobial drug development: implications for the future

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

The economics of parallel trade

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Stoking the antibiotic pipeline.

6 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-8603-9-58

Meeting the challenge of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-8603-9-58

Applying the concepts of financial options to stimulate vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-8603-9-58

Stimulating pharmaceutical research and development for neglected diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-8603-9-58

Vaccine advance-purchase agreements for low-income countries: practical issues.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226193

Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24199835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Improving health r&d financing for developing countries: a menu of innovative policy options

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24199835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1744-8603-9-58

1 reference

2 August 2017

1 reference

2 August 2017

1 reference